News Sentiment

IRWD sentiment intelligence

Ironwood Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 55 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Drug Manufacturers - Specialty & Generic Read-through group
Latest close 4.32 Week of 7 Aug 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

77/100 classification confidence.

Company focus 62

directly relevant articles

Source quality 4

high-authority source matches

Trend context Trend inactive

+2.1% over one week, -3.4% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Ironwood Pharmaceuticals, Inc. $IRWD Shares Sold by Amundi

Market Reaction

Balanced read

63/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 77/100 classification
One-week reaction 2.1% Price confirming higher
Trend fit Trend inactive -3.4% over four weeks
Fair value -13.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 44
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 62
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 16
TradingView 11
MarketBeat 6
simplywall.st 6
Market source 5
Business Wire 4
Seeking Alpha 3
Zacks Investment Research 1

Event Lens

What the news is about

Classified themes
Market update 30
Earnings 21
Guidance 4
Balance sheet 3
Analyst action 2
Deals and strategy 1
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
FinancialContent Direct company coverage

Ironwood Pharmaceuticals, Inc. - Class A Common Stock (IRWD) Stock Price, News, Quote & History

This page provides detailed stock information for Ironwood Pharmaceuticals, Inc. (IRWD), including its current stock price, recent trading activity, and key financial metrics such as market cap, P/E ratio, and volume. The company is a biotechnology firm specializing in gastrointe

Tone
Positive 77/100
Event
Market update
Published
07 Jul 2026 05:10
Source
FinancialContent
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (SWB:I76)

This article provides an overview of Ironwood Pharmaceuticals, Inc. Class A (SWB:I76) including its financial actuals, analyst estimates, and key financial metrics. It covers information on stock performance, future earnings forecasts, past revenue, net income, and employee count

Tone
Positive 58/100
Event
Earnings
Published
30 Jun 2026 04:10
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (BX:I76)

This article provides financial actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (BX:I76), covering income statements, balance sheets, and cash flow data. It includes analyst forecasts, earnings reports, revenue figures, and other financial metrics. The company's

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 05:39
Source
TradingView
TradingView Direct company coverage

I76 Forecast — Price Target — Prediction for 2027

This article provides a forecast for Ironwood Pharmaceuticals, Inc. Class A (I76), including analyst price targets and predictions for 2027. It details earnings, revenue, and net income figures, and answers frequently asked questions about the company's stock, historical prices,

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

Ironwood Pharmaceuticals, Inc. Class A Actuals & Estimates (MUN:I76)

This article provides actuals and estimates for Ironwood Pharmaceuticals, Inc. Class A (MUN:I76), covering financial data, analyst forecasts, and company details. It includes information on earnings, revenue, net income, and dividend policy, as well as an overview of its stock pe

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 20:10
Source
TradingView
Stock Titan Direct company coverage

Director Catherine Moukheibir receives 63,481 Ironwood (IRWD) restricted shares

Ironwood Pharmaceuticals director Catherine Moukheibir has received an equity award of 63,481 shares of Class A common stock, granted as restricted stock with no cash cost. These shares will vest in full on the day before the next annual stockholders' meeting, requiring her conti

Tone
Neutral 50/100
Event
Balance sheet
Published
21 Jun 2026 03:10
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) adds 10M shares to 2019 equity incentive plan

Ironwood Pharmaceuticals (IRWD) announced that its stockholders approved an amendment to the 2019 Equity Incentive Plan, adding 10 million shares of Class A common stock for future equity-based compensation. This approval occurred at the 2026 Annual Meeting of Stockholders, where

Tone
Neutral 50/100
Event
Regulatory and legal
Published
18 Jun 2026 20:14
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (IRWD) director Jay Shepard receives 63,481-share restricted stock grant

Ironwood Pharmaceuticals director Jay Shepard has been granted 63,481 restricted Class A common shares as equity compensation, with no cash cost. The grant was made under the company's Second Amended and Restated Non-employee Director Compensation Policy and vests in full before

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jun 2026 21:41
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) director awarded restricted stock that vests before next meeting

Ironwood Pharmaceuticals director Alexander J. Denner was awarded restricted Class A Common Stock as non-cash compensation, with two grants on June 15 and June 16, 2026, totaling 67,546 shares. These shares were issued under the company's Non-employee Director Compensation Policy

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (IRWD) director Marla Kessler receives 63,481-share restricted stock grant

Ironwood Pharmaceuticals director Marla L. Kessler was granted 63,481 shares of Class A Common Stock as restricted stock. This award was part of the company’s non-employee director compensation policy and vests in full before the next annual stockholders' meeting. Following this

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) director granted 63,481 restricted shares in latest Form 4

Ironwood Pharmaceuticals director Jon R. Duane was granted 63,481 shares of Class A Common Stock as equity compensation, as disclosed in a recent Form 4 filing. These restricted shares, awarded at $0.00, will vest fully on the day before the next annual stockholders' meeting, inc

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (NASDAQ: IRWD) director sells shares and receives new stock grant

Ironwood Pharmaceuticals Inc. director Julie McHugh reported both a sale and a grant of Class A Common Stock. She sold 21,571 shares at a weighted average price of $3.73 under a pre-arranged Rule 10b5-1 trading plan and received a grant of 63,481 restricted shares. After these tr

Tone
Neutral 50/100
Event
Market update
Published
17 Jun 2026 21:09
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) director receives 63,481-share grant

Ironwood Pharmaceuticals director Mark G. Currie was granted 63,481 shares of Class A common stock as restricted stock, awarded at no cash cost as part of his director compensation. Following this award, Currie directly holds 676,900 shares of Ironwood common stock. The restricte

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jun 2026 21:09
Source
Stock Titan
TradingView Direct company coverage

IRWD: Apraglutide and LINZESS drive growth, with new trials, debt reduction, and market leadership ahead

Ironwood Pharmaceuticals, Inc. (IRWD) anticipates a strong year with projected net sales growth and debt reduction. The company expects continued strong performance from LINZESS and the advancement of Apraglutide into a new confirmatory trial, positioning it for potential class l

Tone
Positive 72/100
Event
Guidance
Published
02 Jun 2026 10:10
Source
TradingView
Stock Titan Direct company coverage

Ironwood Pharmaceuticals (IRWD) sets interim CFO fee and RSU grant

Ironwood Pharmaceuticals (IRWD) has amended a prior report to detail the compensation for Ronald Silver in his new role as interim chief financial officer. He will receive a monthly interim assignment fee of $12,250 and was granted 25,000 restricted stock units (RSUs) on May 19,

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Ironwood (IRWD) PFO Ronald Silver receives 25,000-share restricted stock grant

Ronald Silver, PFO & PAO of Ironwood Pharmaceuticals Inc. (IRWD), has been granted 25,000 shares of restricted common stock as equity compensation. This award, valued at $0.00 per share, vests in two equal installments on each approximate anniversary of the grant date. Following

Tone
Neutral 50/100
Event
Market update
Published
21 May 2026 20:12
Source
Stock Titan
Business Wire Direct company coverage

Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026

Ironwood Pharmaceuticals will present data from its LANDMARK survey at Digestive Disease Week® 2026, focusing on healthcare professionals' insights into the burden of total parenteral nutrition for short bowel syndrome patients. The company will also share long-term safety and to

Tone
Positive 66/100
Event
Market update
Published
17 May 2026 07:39
Source
Business Wire